This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
ECOG 4599 was a completed study involving blood and tissue samples from patients with locally advanced, metastatic, or recurrent non-small cell lung cancer treated with bevacizumab, carboplatin, and paclitaxel. The registry describes laboratory and molecular analyses intended to examine the correlation of study results with response and toxicity.
| Feature | ECOG 4599 |
|---|---|
| Study status | Completed |
| Condition | Lung Cancer |
| Study population | Patients with locally advanced, metastatic, or recurrent non-small cell lung cancer |
| Enrollment | 180 |
| Lead sponsor | ECOG-ACRIN Cancer Research Group |
| Sponsor type | Network |
| Study start | March 15, 2008 |
| Primary completion | April 15, 2009 |
| ClinicalTrials.gov | NCT00900172 |
2. Clinical Question
The registry's central scientific question concerns whether results from blood and tissue sample analyses correlate with response and toxicity in patients with locally advanced, metastatic, or recurrent non-small cell lung cancer treated with bevacizumab, carboplatin, and paclitaxel.
Population
Patients with locally advanced, metastatic, or recurrent non-small cell lung cancer.
Treatment context
Patients treated with bevacizumab, carboplatin, and paclitaxel.
Biological measurements
The registry identifies gene expression analysis, polymerase chain reaction, polymorphism analysis, and laboratory biomarker analysis.
Primary question
Whether the study's sample-analysis results correlate with response and toxicity.
3. Trial Design
The registry describes ECOG 4599 as a study of blood and tissue samples from treated patients. It does not provide, in the information reported for this record, a randomized treatment allocation, comparator arm, factorial structure, crossover scheme, or treatment-arm sample sizes.
4. Interventions and Laboratory Analyses
The registry lists both the clinical treatments associated with the study population and several biological or laboratory interventions.
| Category | Registry-listed intervention | Type |
|---|---|---|
| Clinical treatment | Bevacizumab | Biological |
| Clinical treatment | Carboplatin | Drug |
| Clinical treatment | Paclitaxel | Drug |
| Molecular analysis | Gene expression analysis | Genetic |
| Molecular analysis | Polymerase chain reaction | Genetic |
| Molecular analysis | Polymorphism analysis | Genetic |
| Laboratory analysis | Laboratory biomarker analysis | Other |
The presence of several molecular and laboratory techniques indicates that the statistical interpretation may involve linking biological measurements to clinical outcomes. The registry, however, does not provide the individual biomarkers, assay-level definitions, measurement scales, or prespecified modeling specifications needed to describe a particular biomarker analysis in greater detail.
5. Primary Endpoint
| Endpoint | Registry definition | Time frame |
|---|---|---|
| Correlation of results to response and toxicity | Correlation of results to response and toxicity | 1 month |
This endpoint is substantially different from a conventional time-to-event endpoint such as overall survival or progression-free survival. Its wording indicates an interest in relating study results to clinical response and toxicity. The registry does not specify the response definition, toxicity grading system, biomarker variables, correlation coefficient, regression model, or multiplicity strategy used for those relationships.
6. Planned Analysis
The registry identifies correlation of results to response and toxicity as the primary endpoint with a 1-month time frame. No formal statistical analyses are posted to ClinicalTrials.gov.
How an endpoint of this type is typically analyzed
A correlation endpoint requires two clearly defined quantities: a biological or laboratory result and a clinical outcome. The appropriate statistical method depends on the measurement scale of both variables.
| Outcome structure | Typical statistical approach | What it answers |
|---|---|---|
| Continuous biomarker and continuous clinical measure | Pearson or Spearman correlation, depending on distribution and measurement assumptions | Whether higher or lower biomarker values are associated with higher or lower clinical measurements |
| Continuous biomarker and binary response | Logistic regression or a prespecified group comparison | Whether biomarker values differ systematically according to response status |
| Categorical biomarker and binary response | Contingency-table analysis or logistic regression | Whether response frequency differs across biomarker categories |
| Biomarker and toxicity category | Ordinal or binary regression, contingency-table methods, or another model appropriate to the toxicity definition | Whether biomarker characteristics are associated with toxicity classification |
| Multiple biomarkers | Multivariable modeling and prespecified multiplicity control where appropriate | Whether associations persist after accounting for other variables and repeated testing |
These are general statistical approaches for correlation questions; the registry does not identify which of them was used for ECOG 4599.
7. Statistical Methodology
Correlation as an association problem
At its simplest, a correlation analysis asks whether two measured quantities tend to vary together. For two continuous variables, a common descriptive measure is Pearson's correlation coefficient:
The coefficient ranges from −1 to +1. Values near +1 indicate a strong positive linear association, values near −1 indicate a strong negative linear association, and values near 0 indicate little linear association.
For biomarker research, however, the choice of correlation coefficient should follow the scale and distribution of the variables. Spearman's rank correlation can be more appropriate when measurements are ordinal, strongly non-normal, or when a monotonic rather than strictly linear relationship is of interest.
Response as an outcome
If response is defined as a binary outcome, such as response versus no response, a correlation coefficient between two continuous measurements may not be the most informative analysis. Logistic regression is one common framework because it directly models the probability of response as a function of a biomarker or other covariates.
Here, X represents a biomarker or other predictor and β1 describes how the log-odds of the outcome change with that predictor.
The clinically useful quantity would often be an odds ratio, probability difference, or predicted probability at clinically meaningful biomarker values rather than the regression coefficient alone.
Toxicity as an outcome
Toxicity may be binary, ordinal, categorical, continuous, or time-dependent depending on how it is defined. Each structure calls for a different statistical approach. For example, an ordinal toxicity outcome can motivate ordinal regression, whereas a binary toxicity outcome can be modeled with logistic regression.
Continuous versus categorized biomarkers
A continuous biomarker contains more information than a version split into arbitrary "high" and "low" groups. Categorization can make results easier to display, but it can also reduce statistical power and make results sensitive to the selected threshold. If a threshold is used, its clinical or prespecified justification matters.
Multivariable adjustment
Observed biomarker-response associations can reflect other patient or disease characteristics. A multivariable model can be useful when important covariates are known and the sample size supports adjustment. The model should be specified with care because adding many predictors to a modest sample can produce unstable estimates.
Missing biomarker measurements
Biomarker studies frequently have incomplete laboratory measurements. The statistical consequences depend on why measurements are missing and how much information is absent. Complete-case analysis, missing-indicator approaches, multiple imputation, and model-based methods have different assumptions and should not be treated as interchangeable.
8. Statistical Methods Explained
What does "correlation" mean in this study?
Correlation means examining whether measured study results vary systematically with clinical response or toxicity. It does not automatically imply that one variable causes the other. The strength and direction of an association must be interpreted in the context of how the variables were measured.
Why might Pearson correlation not always be appropriate?
Pearson correlation describes linear association between continuous measurements. If a biomarker is ordinal, highly skewed, affected by outliers, or related to the outcome in a nonlinear but monotonic manner, another approach such as Spearman correlation may be more suitable.
Why use logistic regression for response?
If response is represented as a yes/no outcome, logistic regression directly models the probability of response. It can also incorporate continuous biomarker measurements without forcing them into arbitrary categories and can adjust for additional covariates when justified.
Why is toxicity statistically different from response?
Response and toxicity can have different measurement structures. Response might be binary or categorical, while toxicity could be graded or ordinal. The statistical model should reflect the actual outcome scale rather than treating all clinical outcomes as the same type of variable.
Why are multiple biomarkers a statistical challenge?
Testing many biomarkers creates multiple opportunities for apparently unusual associations to arise by chance. If numerous hypotheses are examined, the nominal significance level for an individual test may no longer describe the probability of at least one false-positive finding across the complete set of tests. Prespecification and multiplicity control can therefore be important.
Why does association not establish causation?
A biomarker can be associated with response because it reflects disease severity, treatment exposure, another biological pathway, or another characteristic that affects the outcome. Randomized treatment allocation can support causal treatment comparisons, but an observational biomarker association within treated patients does not automatically provide the same causal protection.
9. Interpreting a Correlation Result
An association statistic summarizes how two variables relate within the analyzed sample. Its magnitude should be considered together with its uncertainty, the scale of measurement, the number of observations, and the model assumptions.
A statistically detectable association does not mean that the biomarker predicts every patient's outcome, that changing the biomarker would change the outcome, or that the biomarker is suitable for clinical decision-making.
An estimate based on a relatively small number of informative observations can be imprecise even when the point estimate appears substantial. Confidence intervals communicate that uncertainty more directly than a point estimate alone.
A p-value addresses compatibility with a specified null hypothesis under a statistical model. It does not quantify the strength of a biological association or the clinical importance of the finding. Effect estimates and their confidence intervals are therefore essential for interpretation.
10. Endpoint Timing and the 1-Month Window
The registry gives a 1-month time frame for the primary endpoint, "Correlation of results to response and toxicity." This timing should be kept distinct from the broader study duration.
Study start
The registry lists March 15, 2008 as the study start date.
Primary endpoint time frame
The registry specifies a 1-month time frame for correlation of results to response and toxicity.
Primary completion
The registry lists April 15, 2009 as the primary completion date.
The one-month endpoint window should not be interpreted as the total duration of the study. It is the registry's stated time frame for the primary endpoint, while the study itself had a longer enrollment and completion period.
11. Results Status
Accordingly, the statistical interpretation of ECOG 4599 rests on understanding the endpoint and the appropriate analytical framework rather than on an observed effect estimate. The absence of a posted statistical analysis means that no numerical association can be characterized from the ClinicalTrials.gov record.
12. Safety and Toxicity as Statistical Outcomes
Toxicity is explicitly part of the primary endpoint wording, making it an important statistical outcome in this study. The registry identifies the treatment context as bevacizumab, carboplatin, and paclitaxel, but it does not provide serious adverse-event counts by arm, toxicity frequencies, toxicity grades, confidence intervals, or formal safety comparisons.
| Safety information | What the registry reports |
|---|---|
| Toxicity in primary endpoint | Included in "Correlation of results to response and toxicity" |
| Serious adverse events by arm | Not reported in the available registry information |
| Toxicity grade distribution | Not reported in the available registry information |
| Formal safety comparison | No posted statistical analysis |
| Numerical toxicity estimates | Not reported in the available registry information |
Statistically, toxicity can be analyzed as an outcome in its own right or as part of a biomarker-association analysis. The distinction matters because a biomarker associated with toxicity is answering a different question from the overall frequency of toxicity in the treated population.
13. Biomarker Analysis: Key Statistical Considerations
Measurement quality
Biomarker analyses depend on the reliability, reproducibility, and scale of the underlying laboratory measurement. Measurement error can weaken observed associations.
Outcome definition
The response and toxicity definitions determine which statistical model is appropriate. A binary, ordinal, continuous, or time-to-event outcome requires a different analytical framework.
Confounding
A biomarker may be associated with clinical characteristics that also affect response or toxicity. Adjustment can be important when those covariates are known and appropriately measured.
Multiple testing
Multiple biomarkers or molecular measurements increase the number of statistical hypotheses and can increase the chance of false-positive findings.
Continuous biomarkers preserve information
Suppose a laboratory measurement is available on a continuous scale. Modeling it continuously generally preserves more information than immediately converting it into two categories. Categorization can conceal nonlinear relationships, reduce precision, and produce different conclusions depending on the selected cutoff.
Nonlinear associations
A biomarker-response relationship does not have to be linear. If the clinical relationship changes sharply at particular values or follows a curved pattern, a linear correlation or linear regression term may not adequately describe it. Flexible regression methods can sometimes address this issue when the sample size and study design support them.
Validation
A biomarker that appears associated with response or toxicity in one dataset should ideally be evaluated in an independent population before being treated as a reproducible predictive marker. Statistical significance in a discovery analysis is not equivalent to external validation.
14. Analysis Populations and Missingness
The registry identifies enrollment of 180 patients but does not provide the number with evaluable blood or tissue samples, the number with complete laboratory measurements, or the number with evaluable response or toxicity information.
| Population or quantity | Registry information |
|---|---|
| Total enrollment | 180 |
| Patients with evaluable biomarker results | Not reported in the available registry information |
| Patients included in a formal correlation analysis | Not reported in the available registry information |
| Missing laboratory measurements | Not reported in the available registry information |
| Missing response or toxicity observations | Not reported in the available registry information |
This distinction is statistically important. Enrollment is not necessarily identical to the number contributing usable observations to a particular biomarker analysis. If laboratory measurements are unavailable for some patients, the effective sample size for an association analysis can be smaller than the total enrollment.
15. Statistical Power and Precision
The total enrollment of 180 provides the broad size of the study population, but the precision of a biomarker-response or biomarker-toxicity estimate depends on the number of patients with usable measurements and the distribution of the outcomes.
The actual precision also depends on outcome frequency, measurement variability, model complexity, missingness, and the number of statistical comparisons.
A rare response or toxicity outcome can produce unstable estimates even in a study with a moderate overall enrollment. Conversely, a common outcome with reliable measurements can provide more information about an association. The registry does not report the event frequencies or analyzable biomarker sample sizes needed for a numerical power assessment.
16. Limitations
- No posted formal statistical analysis: the ClinicalTrials.gov record does not provide numerical results or formal statistical tests for the primary endpoint.
- Endpoint specificity: "Correlation of results to response and toxicity" does not by itself specify the biomarker variables, response definition, toxicity definition, or statistical model.
- Unknown evaluable sample: the record reports enrollment of 180 but does not state how many participants contributed usable observations to a particular laboratory correlation analysis.
- Potential multiplicity: the study includes several types of molecular and laboratory analyses. If multiple biomarkers or hypotheses were tested, multiplicity could affect the interpretation of nominal statistical findings.
- Association is not causation: a biomarker associated with response or toxicity does not necessarily cause the observed clinical outcome.
- Measurement error: laboratory variability can attenuate or distort observed biomarker-outcome relationships.
- Missing data: incomplete sample availability or clinical outcome information can affect both precision and representativeness.
- Model dependence: the appropriate analysis depends on the measurement scale and distribution of the biomarker and outcome.
17. Why This Trial Matters Statistically
ECOG 4599 illustrates an important class of clinical-trial statistics: translational analyses that connect biological measurements with clinical outcomes. Unlike a simple two-arm treatment comparison, the central question here concerns whether measurable biological characteristics are associated with response and toxicity in a treated population.
| Concept | How it appears in ECOG 4599 |
|---|---|
| Biomarker analysis | Gene expression, polymerase chain reaction, polymorphism, and laboratory biomarker analyses are listed. |
| Clinical response | Response is explicitly included in the primary endpoint wording. |
| Toxicity analysis | Toxicity is explicitly included in the primary endpoint wording. |
| Correlation | The primary endpoint is "Correlation of results to response and toxicity." |
| Outcome modeling | The appropriate method depends on whether response or toxicity is continuous, binary, ordinal, categorical, or otherwise defined. |
| Multiplicity | Multiple laboratory and molecular measurements can create multiple statistical hypotheses. |
| Missing data | Sample availability and evaluability can affect the number of observations contributing to biomarker analyses. |
| External validation | Associations identified in a study population require independent evaluation before broader predictive claims are justified. |
18. Statistical Interpretation vs Clinical Interpretation
Statistical interpretation
The registry defines a correlation endpoint linking study results with response and toxicity. The appropriate statistical analysis depends on the measurement scales and prespecified definitions of the biological and clinical variables.
Clinical interpretation
A biomarker-response or biomarker-toxicity association, if demonstrated, would describe a relationship within the studied population. Clinical usefulness would require consideration of reproducibility, magnitude, uncertainty, biological plausibility, and independent validation.
19. What a Complete Statistical Analysis Would Need to Report
For a correlation-based translational endpoint to be fully interpretable, several elements would ordinarily be reported alongside the point estimate.
| Element | Why it matters |
|---|---|
| Biomarker definition | Establishes exactly what biological quantity was measured and on what scale. |
| Clinical response definition | Determines what constitutes the outcome being correlated with the biological measurement. |
| Toxicity definition | Determines the statistical structure of the safety outcome. |
| Analysis population | Shows which enrolled patients actually contributed to the analysis. |
| Effect estimate | Quantifies the magnitude and direction of the association. |
| Confidence interval | Shows uncertainty around the estimated association. |
| Hypothesis test | Provides a formal assessment relative to a specified null hypothesis when such a test is appropriate. |
| Multiplicity strategy | Clarifies how repeated biomarker hypotheses were handled. |
| Missing-data method | Explains how incomplete laboratory or clinical observations were treated. |
| Validation strategy | Determines whether the finding was evaluated beyond the discovery dataset. |
The ClinicalTrials.gov record does not provide these analytical details for the primary endpoint, so the statistical interpretation should remain at the level of the endpoint definition and appropriate methodological framework.
20. Sources
- ClinicalTrials.gov: NCT00900172 — ECOG 4599.
Continue through the Clinical Biostats knowledge graph
Explore clinical-trial statistical methods, endpoint analysis, and biomarker methodology across the Clinical Biostats library.
21. Record Summary
ECOG 4599 is a completed study with 180 enrolled patients investigating blood and tissue sample analyses in patients with locally advanced, metastatic, or recurrent non-small cell lung cancer treated with bevacizumab, carboplatin, and paclitaxel. The registry's primary endpoint is "Correlation of results to response and toxicity" with a 1-month time frame. The statistical problem is therefore fundamentally one of relating biological measurements to clinical outcomes.
The most important statistical considerations are the definition and measurement of the biomarker, the precise response and toxicity outcomes, the number of evaluable observations, the appropriate regression or correlation framework, missing data, multiple testing, and the distinction between association and causation. Because no formal statistical analyses are posted to ClinicalTrials.gov, the registry record does not provide numerical estimates with which to quantify the strength or precision of those associations.